RxDoctor Payments Data

Antonela Barbu, MD

Family Medicine · Fairfield, CTNPI 1861655466

Payments from drug & device makers

$517in general payments, 2019–2025

Across 14 payments — averaging $36.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$166
  • Lilly USA, LLC$125
  • Johnson & Johnson$117
  • Amgen$53
  • Boehringer Ingelheim$30
  • Pfizer$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$517 in reported general payments places this provider in the 60th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$75,502
Medicare patients
176
Services billed
836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide47$74,583
OzempicSemaglutide45$52,785
EliquisApixaban40$44,486
GemtesaVibegron24$23,190
MounjaroTirzepatide15$22,515
JardianceEmpagliflozin16$20,948
JanuviaSitagliptin Phosphate13$20,445
TrulicityDulaglutide13$16,647
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,020
Breo ElliptaFluticasone/Vilanterol24$13,107
Tresiba Flextouch U-100Insulin Degludec12$6,819
TrintellixVortioxetine Hydrobromide11$5,287
SynthroidLevothyroxine Sodium50$4,334
Levothyroxine Sodium259$3,156
Atorvastatin Calcium259$2,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$44,48640 claims
Lilly USA, LLCMounjaro, Trulicity$125$39,16228 claims
Boehringer IngelheimJardiance$30$20,94816 claims
AbbVieSynthroid$166$4,33450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →